



PII: S0960-894X(97)00149-2

Benzothiadiazine Dioxide Acyclonucleosides as Lead Compounds for the Development of New Agents Against Human Cytomegalovirus and Varicella-Zoster Virus Infections

Ana Martinez,^{a,*} Ana I. Esteban^a and Erik De Clercq^b^a Instituto de Química Médica (CSIC), Juan de la Cierva 3, 28006 Madrid (Spain)^b Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven (Belgium)

Abstract- The first acyclonucleosides derived from 2,1,3-benzothiadiazine dioxides were synthesized. From their antiviral activity evaluation results these compounds might be considered as new leads in the search for inhibitors of human cytomegalovirus (CMV) and varicella-zoster virus (VZV) infections.


© 1997 Elsevier Science Ltd.

Cytomegaloviruses (CMVs) are highly species-specific DNA viruses that are found universally throughout the world and that commonly infect many animals, including humans. In the vast majority of cases the initial infection is asymptomatic. However, HCMV can cause severe morbidity and mortality in congenitally infected newborns and immuno-compromised patients.¹ Individuals infected with HIV are nearly always HCMV seropositive and often develop symptomatic reactivation disease as immunocompromise progresses. Nucleoside analogues offer great potential for the treatment of herpes- and retrovirus infections.^{2,3} For the treatment of CMV infections, the acyclonucleoside ganciclovir, the phosphonate foscarnet and, since a few months, the

acyclonucleoside phosphonate cidofovir have been approved, although the use of ganciclovir and foscarnet has been compounded by their toxicity and the emergence of virus-drug resistances.⁴

Continuing with our work on acyclic nucleosides,⁵ here we report the first synthesis and antiviral evaluation of acyclonucleosides derived from the benzothiadiazine dioxide ring.⁶

The acyclonucleosides were obtained using



* To receive all correspondence. FAX 34-1-5644853. E-mail: IQMAM06@PINAR1.CSIC.ES

the silylation procedure.⁷ Several acyclic moieties have been introduced,⁸ including acetoxyethoxymethyl, benzyloxymethyl and propargyloxymethyl fragments. In all conditions assayed, acycloglycosylation took place initially at N-3 (Scheme 1). The N-1 substituted acyclic nucleosides were prepared using a protection-deprotection strategy from 3-benzylbenzothiadiazine. A lipase-mediated deacylation was employed as deprotection procedure for the acyclic moiety. This previously described methodology⁹ has been applied to the regioselective deacylation of a thiadiazine dioxide diacyclic nucleoside related to 6-methyluracil.¹⁰

The new benzothiadiazine acyclonucleosides prepared were evaluated for their activity against cytomegalovirus (CMV, strains AD-169 and Davis) and varicella-zoster virus (VZV, strains OKA, YS, 07/1 and YS/R) in human embryonic lung (HEL) cells¹¹ whilst their potential anti-HIV activity was evaluated (HIV-1, strain III_B and HIV-2, strain ROD) in MT-4 cells.¹¹ Compounds **7**, **8**, **15** and **16** showed activity against CMV and VZV at concentrations that were 5 to 10-fold below the cytotoxic concentrations for the host cells. Benzylacyclonucleoside **16** showed activity against CMV at a concentration that was >10-fold lower than the concentration that was toxic to the host cells. This activity may therefore qualify as a specific antiviral effect. Additionally, derivative **16** inhibits the replication of HIV-1 in MT-4 cells with a IC₅₀=3.7 µg/ml. All the compounds proved to be inactive against the replication of HIV-2 at subtoxic concentrations in MT-4 cells. The structure of these active compounds is quite unique not only for the nature of the heterocyclic base, but also because of the lack of the OH group in the acyclic counterpart specially regarding the anti-CMV activity. The HIV-1 specific nature found in this kind of acyclonucleosides probably implies binding at the NNRTI site.

Benzothiadiazine dioxides acyclonucleosides might be considered as new lead compounds in the search for inhibitors of human cytomegalovirus and varicella-zoster virus infections, which are among the most common opportunistic infections in patients suffering from the acquired immune deficiency syndrome (AIDS), taking profit of the anti-HIV-1 specific activity found.

Further efforts are directed at determining the structure-activity relationship of this new family of compounds and discovering new congeners with higher antiviral potency.

Acknowledgement: This work was financially supported by CICYT (projects no. SAF 93/710 and SAF 96/107) and E.U. (project no. PL-951634).

References and Notes

1. Van der Meer, J.T.M.; Drew, W.L.; Bowden, R.A.; Galasso, G.J.; Griffiths, P. *Antivir. Res.* **1996**, *32*, 119.
2. Boehme, R.E.; Borthwick, A.D.; Wyatt, P.G. *Ann. Rep. Med. Chem.* **1995**, *30*, 139.
3. De Clercq, E. *Rev. Med. Virol.* **1995**, *5*, 149.
4. Field, A.K.; Biron, K.K. *Clin. Microbiol. Rev.* **1994**, *7*, 1.
5. Esteban, A.I.; Juanes, O.; Conde, S.; Goya, P.; De Clercq, E.; Martinez, A. *Bioorg. Med. Chem.* **1995**, *3*, 1527.
6. Esteban, A.I.; De Clercq, E.; Martinez, A. Presented at First International Symposium on New Horizons of Organic Chemistry in Biomedicine, Santiago de Compostela (Spain), **1996**.
7. Vorbrüggen, H.; Niedballa, U. *J. Org. Chem.* **1974**, *39*, 3664.
8. *General procedure for the synthesis of benzothiadiazine acyclonucleosides:* To a solution in CH₂Cl₂ (25 mL) of the silyl derivative of the benzothiadiazine dioxide (1 mmol) prepared by refluxing the base in hexamethyldisilazane (3 mL) under nitrogen using suitable catalyst and co-solvents, the dissolved acyclic moiety precursor (25 mL) was added. The mixture was cooled and BF₃Et₂O was added under vigorous stirring and exclusion of moisture. The resulting mixture was stirred at room temperature for 1 to 3 hours, and then was worked up in each particular case.
9. De la Cruz, A.; Elguero, J.; Gotor, V.; Goya, P.; Martinez, A.; Moris, F. *Synth. Commun.* **1991**, *21*, 1477.
10. Esteban, A.I.; Juanes, O.; Conde, S.; Martinez, A. *Tetrahedron*, **1994**, *48*, 13865.
11. De Clercq, E., in Minutes of an European Symposium, Editors: D. Crommelin, P. Couvreur and D. Duchene, Editions de Santé, Paris, France **1994**, pp 108.

(Received in Belgium 12 November 1996; accepted 17 March 1997)

Comp.	Antiviral Activity IC ₅₀ (μg/ml)	Cytotoxicity CC ₅₀ (μg/ml)	
CMV			
	AD-169	Davis	
7	11	12	>50
8	8.4	11	>50
15	12	12	24
16	3.6	3.6	>50
Ganciclovir	1.2	1.3	>50
TK-VZV			
	07/1	YS/R	
7	11	13	>50
8	>5	>5	>50
15	>12	>12	24
16	>5	3	>50
Aciclovir	24	26	200
HIV-1 (IIIB)			HIV-2 (ROD)
7	>8	>8	25
8	>8	>8	23
15	79.3	>86	>125
16	3.7	>99	>125